Annovis Bio Secures $10 Million to Advance Neurodegenerative Disease Treatment Through 2027

Annovis Bio Inc., a clinical-stage biotechnology company, has closed an underwritten public offering that raised approximately $10 million in gross proceeds. The financing, combined with existing cash and a recent $1.5 million investment from Board Chair Michael Hoffman, is expected to extend the company’s cash runway through the second quarter of 2027. This financial stability supports operations through a key six-month symptomatic data readout from its Phase 3 Alzheimer’s trial and the anticipated New Drug Application submission to the U.S. Food and Drug Administration.

The company is developing buntanetap, an investigational once-daily oral therapy for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. Buntanetap works by inhibiting the translation of multiple neurotoxic proteins—such as APP and amyloid beta, tau, alpha-synuclein, and TDP-43—through a specific RNA-targeting mechanism. By addressing these underlying causes of neurodegeneration, the treatment aims to halt disease progression and improve cognitive and motor functions in patients.

The funding ensures that Annovis Bio can continue advancing its ongoing clinical studies and regulatory preparations without financial interruption. The company’s lead drug candidate represents a novel approach in the field, as it targets multiple pathological proteins simultaneously rather than focusing on a single target. This multi-target strategy could potentially address the complex nature of neurodegenerative diseases more effectively than current therapies.

For more information about Annovis Bio and its research, visit https://www.annovisbio.com. The company’s latest news and updates are available through specialized communications platforms that focus on biotechnology developments, though investors should review all available information carefully. The extended financial runway through 2027 provides the company with stability during a critical period of clinical development and regulatory review for its potentially transformative treatment.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Annovis Bio Secures $10 Million to Advance Neurodegenerative Disease Treatment Through 2027.

The post Annovis Bio Secures $10 Million to Advance Neurodegenerative Disease Treatment Through 2027 appeared first on citybuzz.